Asset Details
Do you wish to reserve the book?
Reassessing the risk of natalizumab-associated PML
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reassessing the risk of natalizumab-associated PML
Do you wish to request the book?
Reassessing the risk of natalizumab-associated PML
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reassessing the risk of natalizumab-associated PML
2016
Overview
The risk algorithm for natalizumab-associated PML was first established in 2012 using the observations that JC virus antibody status, prolonged duration of natalizumab therapy (>2 years), and prior exposure to immunosuppressive therapy increased the risk for the disease. Prior to the publication of Biogen’s algorithm, a risk algorithm was created by Fox and Rudick using an Excel spreadsheet in order to address the concerns of their patients. Applying the most recently available data regarding natalizumab-associated PML, the risk assessments for PML were recalculated. The current numbers indicate substantially higher risks for PML in 2015 than in 2012. Our calculations suggest that an individual having all three risk factors has an approximately 1 in 44 chance of developing PML.
Publisher
Springer International Publishing,Nature Publishing Group
Subject
/ Biomedical and Life Sciences
/ Humans
/ JC virus
/ JC Virus - growth & development
/ Leukoencephalopathy, Progressive Multifocal - chemically induced
/ Leukoencephalopathy, Progressive Multifocal - diagnosis
/ Leukoencephalopathy, Progressive Multifocal - pathology
/ Leukoencephalopathy, Progressive Multifocal - virology
/ Natalizumab - administration & dosage
/ Natalizumab - adverse effects
/ Patients
/ Seroconversion - drug effects
/ Serology
/ Virology
